Designation of hospitals for complex visceral surgery in Switzerland

15

Mar 2019

In mid-February 2019, the Swiss conference of cantonal healthcare directors (GDK/CDS) has published information about allocation of hospitals for highly complex visceral surgery in the fields of oesophageal, pancreatic and hepatic resections. Partial areas of deep rectal resections and complex bariatric surgery have to be reassessed by this unit. The decision has been brought by the decision-making body for highly specialized medicine (HSM) of the GDK/CDS.

This decision is based on the decision of the same decision-making body of February 2016. Since then, the criteria for awarding benefits had been defined, and an application procedure has been organized. In addition to specific requirements for the services concerned (such as the quality of structures and processes, participation in teaching activities, postgraduate training and research, the obligation to maintain a register, etc.), for all five partial domains, a minimum of twelve procedures per year has been fixed, calculated on an average of three years. 

Seventeen hospitals (out of 26 who applied) were awarded the liver resection procedures. Eight (8) (out of 20) were awarded the esophageal procedures, and eighteen (18) (out of 29) were awarded the pancreatic resection. Regarding deep rectal resections and complex bariatric surgery, the decision-making body has to reassess these applications, since their first opinion was that none of the applicants could perform these surgeries efficiently. The scientific literature has demonstrated that a rise in quality of these procedures exists; thus the criteria were tightened. Also, the aim is to ensure that rectal resection and complex bariatric surgery concentrate on fewer centers in Switzerland.

The mandates are awarded for a period of six years, starting from August 1, 2019. Until then, the previous cantonal service contracts will apply.

See the whole announcement and the list of hospitals (in French or German) that have been awarded the benefit here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

10

Feb 2022

In January 2022, the Scottish Health Technology Group released a recommendation of the closed-loop systems and the artificial pancreas for type one diabetes mellitus. The limited use of closed-loop systems in routine clinical care makes it difficult to estimate device-related adverse event rates. No evidence was identified for artificial pancreas systems (multi-hormone closed-loop systems) available on the UK market.

Read more

31

Jan 2022

On January 20, 2022, the Academy of Medical Royal Colleges (AoMRC) launched a consultation on the latest set of guidance (List 3) of the Evidence-based Interventions (EBI) Programme. EBI program develops guidance sets (Lists) for tests, treatments, and procedures based on recommendations from the Expert Advisory Committee and NICE assessments. Proposed List 3 covers 17 interventions across a range of medical specialties, including cardiology, ophthalmology, urology, and others. The deadline for comments submission is March 31, 2022.

Read more

10

Jan 2022

On December 20, 2021, the tariff partners of the novel TARDOC reimbursement system for outpatient care (association of health insurers curafutura and association of physicians, FMH) re-submitted the substantially revised version 1.3 of TARDOC to the Federal Council. The tariff partners hope that the Federal Council will assess the new reimbursement system in the first quarter of 2022 and that it could be implemented from January 2023.

Read more

15

Dec 2021

In 2015, the Federal Office for Public Health launched an HTA program intending to reassess the benefits already reimbursed by compulsory health insurance. The following ongoing re-evaluations are in progress: multigene expression tests in breast cancer, cardiac catheterization for coronary artery disease, invasive procedures for coronary artery disease, removal of osteosynthesis materials, etc.

Read more

04

Nov 2021

On September 16, 2021, the Federal Joint Committee (G-BA) has decided that it would not evaluate the proton therapy in a number of indications, including esophageal cancer and inoperable hepatocellular carcinoma (HCC).

Read more